Key Highlights

  • Shares closed up 10.06% at $71.38, outperforming a firmer healthcare sector.
  • The company's 31-valent pneumococcal Vaccine candidate met all primary endpoints in the Phase 3 OPUS-1 trial.
  • The candidate was tested against two existing branded pneumococcal vaccines in the head-to-head study.
  • A $1 billion stock and convertible note financing followed the positive trial results.
  • Analysts at several firms raised price targets into a range of $122 to $163 following the data.

Phase 3 Success Validates the Company's Lead Candidate

Vaxcyte (NASDAQ:PCVX) shares closed sharply higher as investors continued to digest positive Phase 3 OPUS-1 results for the company's 31-valent pneumococcal conjugate vaccine candidate. Vaxcyte is a clinical-stage vaccine innovation company dedicated to engineering high-fidelity, broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases, with pneumococcal disease as its lead franchise.

The candidate met all primary endpoints when tested head-to-head against two existing branded pneumococcal vaccines, a result that analysts have described as a significant de-risking event for the company's broader pipeline strategy.

Billion-Dollar Financing Follows the Positive Data

Following the trial results, the company completed a $1 billion stock and convertible note financing, strengthening its Balance Sheet as it advances toward a planned Biologics license application filing in the first half of 2028. Several research firms, including Jefferies, BofA, Guggenheim, Needham, and Mizuho, raised their price targets on the stock into a range of $122 to $163 following the data and financing news.

Shares Outperform a Firmer Healthcare Sector

Today's gain outpaces a broadly firmer healthcare sector, with shares trading on above-average Volume as investors rotate back into the name following the positive clinical readout. The stock had spiked sharply earlier in the week before a partial pullback, with today's advance extending the broader post-data rally.

Additional Pipeline Readouts Expected Through 2028

Investors are looking ahead to additional Phase 3 readouts for adjacent pneumococcal vaccine candidates, expected in the first half of 2027, along with the planned biologics license application filing in the first half of 2028, as the next milestones in the company's vaccine development program.